Prescient Therapeutics Limited Share Price
Equities
PTX
AU000000PTX3
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 AUD | -10.34% | -11.86% | -16.13% |
03-25 | Transcript : Prescient Therapeutics Limited - Special Call | |
02-23 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 1.89M 1.23M 98.8M | Sales 2023 | 2.43M 1.59M 127M | Capitalization | 65.23M 42.63M 3.41B |
---|---|---|---|---|---|
Net income 2022 | -5M -3.27M -261M | Net income 2023 | -7M -4.58M -366M | EV / Sales 2022 | 47.2 x |
Net cash position 2022 | 12.28M 8.03M 642M | Net cash position 2023 | 21.92M 14.32M 1.15B | EV / Sales 2023 | 17.8 x |
P/E ratio 2022 |
-19.6
x | P/E ratio 2023 |
-8.41
x | Employees | 3 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.49% |
Latest transcript on Prescient Therapeutics Limited
1 day | -10.34% | ||
1 week | -11.86% | ||
Current month | -5.45% | ||
1 month | -5.45% | ||
3 months | -8.77% | ||
6 months | -14.75% | ||
Current year | -16.13% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 27/11/14 | |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Engle
CHM | Chairman | 69 | 27/11/14 |
James Campbell
BRD | Director/Board Member | - | 27/11/14 |
Ellen Feigal
BRD | Director/Board Member | 69 | 14/05/23 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.052 | -10.34% | 1,126,758 |
24/04/24 | 0.058 | +1.75% | 831,801 |
23/04/24 | 0.057 | -3.39% | 1,352,607 |
22/04/24 | 0.059 | 0.00% | 725,004 |
Delayed Quote Australian S.E., April 26, 2024 at 07:10 am
More quotes1st Jan change | Capi. | |
---|---|---|
-16.13% | 27.31M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- PTX Stock